ArticleFrontiers in oncology2026
Clinical analysis of seven cases of primary hepatic neuroendocrine neoplasms.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To summarize the clinical manifestations, imaging features, laboratory findings, pathological characteristics, treatment modalities, and prognosis of primary hepatic neuroendocrine neoplasms (PHNEN). Methods: A retrospective analysis was conducted on the clinical data of 7 patients with PHNEN admitted to The Affiliated Hospital of Qingdao University between June 2015 and July 2023. Data collected included clinical manifestations, imaging features, and laboratory results. Results: The cohort consisted of 4 males and 3 females, with a median age of 54 (53, 64) years. Six patients were asymptomatic, with lesions discovered incidentally during physical examinations, one patient presented with an upper abdominal mass. Six patients had solitary tumors (3 in the left lobe, 3 in the right lobe), and one patient had multiple tumors involving both lobes. Pathologically, there were 5 cases of neuroendocrine tumors (NET), including 4 G2 grade and 1 G1 grade, and 2 cases of Small cell neuroendocrine carcinoma (SCNEC). Arterial phase enhancement was observed in 3/3 patients undergoing contrast-enhanced CT and in 3/4 patients undergoing contrast-enhanced MRI. Immunohistochemical staining showed positivity rates of 7/7 for Syn, 5/5 for CgA, and 5/5 for CD56. Six patients underwent radical surgical resection, while one patient only underwent intraoperative biopsy due to excessively large tumor size. The median follow-up time was 11 (3, 102) months. Among the six patients who underwent radical resection, four showed no recurrence, one recurred at 8 months postoperatively, and one recurred at 96 months postoperatively. These two patients received no further treatment after recurrence and died 2 months and 6 months later, respectively. The patient who only underwent biopsy died 3 months postoperatively. Conclusion: PHNEN lacks specific clinical manifestations, imaging findings, and laboratory test results. Definitive diagnosis relies on pathological examination. Radical surgical resection is an effective treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.